RSS

non-metastatic castration-resistant prostate cancer

Astellas Pharma and Pfizer have announced an amendment to the clinical research protocol for the Phase III PROSPER trial evaluating XTANDI (enzalutamide) in patients with non-metastatic (M0) castration-resistant prostate cancer (CRPC) more

12 Jun 2017 10:45 News